Robert Pullin is a Principal Scientist and Director of Medicinal Chemistry at Recursion, leading scientific teams across various projects. With over 10 years of structure-based drug design experience in the biotech and pharmaceutical sector, Robert is a co-inventor of two clinical candidates for pain treatment, including the FDA-approved Nav1.8 inhibitor VX-548. They have a background as a synthetic organic chemist, having contributed to significant syntheses such as Microsclerodermin J and epi-Picropodophyllin. Robert's academic journey includes an MChem degree from Durham University and a PhD from Imperial College London, complemented by post-doctoral research at the University of Oxford.
This person is not in the org chart
This person is not in any teams
This person is not in any offices